At FFC, we pride ourselves on offering you the most appropriate treatment options available and wanted by you, not the most expensive one. We individualize your treatment by listening to your preferences and presenting you with options. Together, the best treatment option for you is decided and you may be surprised to know that the cast majority of our patients do not start with IVF/ICSI.

We offer ovulation tracking, ovulation induction, sperm donor programs, IVF, ICSI, intrauterine insemination (IUI), sperm suitability assessment for artificial reproductive technology, surgical sperm recover (TESA/PESA), assisted hatching, embryo biopsy, preimplantation genetic testing for aneuploidy (PGT-A) and single gene disorders (PGT-M), freezing and storage of sperm, eggs and embryos, access to “Life Whisperer”, surrogacy, sterilization reversal, and diagnosis and treatment of PCOS and endometriosis.

More details regarding the treatments we offer are available on our Treatment page.

In Vitro Fertilisation is the process of helping people fall pregnant after other means have been exhausted or not clinically indicated. Almost 1 in 20 babies in Australia are born through IVF.

After a series of injections, eggs are recovered and are combined with sperm outside of the body (in vitro) to aid fertilisation. Fertilised eggs are grown in a protected environment in a lab for several days before being transferred into the woman’s uterus, or frozen for future cycles. IVF is the most effective form of assisted reproductive technology, and can be done with you and your partners own eggs/sperm, or with our donors. We are happy to discuss your options with you, and create a customised treatment plan specifically suited to your needs and medical requirements.

Ovarian Hyperstimulation Syndrome (OHSS) is a potential complication of IVF treatment, but may also occur after other types of treatment, or rarely in a natural cycle. IVF is essentially hyper-stimulating the ovaries to develop 8-15 eggs, rather than one occurring in a non stimulated cycle, so mild symptoms are to be expected. OHSS usually resolves after 7-10 days, but at FFC, we are focused on preventing OHSS. Speak with our nurses for more information on how we monitor and prevent OHSS.

Polyendocrine Metabolic Ovarian Syndrome (PMOS) is the new name for the condition previously known as Polycystic Ovarian Syndrome (PCOS). It is a common hormonal disorder affecting around 1 in 8 women, and is one of the leading causes of fertility problems in a female’s reproductive years.

PMOS can cause irregular menstrual cycles, excess hair growth, acne and many small follicles in the ovaries. Despite the old name, these follicles are not cysts. The hormonal differences seen in women with PMOS affect ovulation and can cause difficulty when trying to conceive.

Fortunately, we are able to treat PMOS with oral tablets and/or follicle stimulating hormone (FSH) to release eggs. Diet and exercise can also help improve fertility and ovulation in women with PMOS.

The condition itself has not changed, only its name. If you have been diagnosed with PCOS, you have PMOS. If you suspect you may have PMOS, or have previously been diagnosed with PCOS, call us to book an appointment with our team for management and further information.

In May 2026, an international consensus renamed Polycystic Ovarian Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS). The new name better describes what the condition actually is:

• Polyendocrine reflects that several hormone systems are involved, not just the ovaries
• Metabolic reflects the effects on insulin, energy use and weight
• Ovarian reflects the impact on ovulation and ovarian function

The old name focused attention on “cysts” that are not, in fact, cysts. They are follicles, and they are a normal part of ovarian structure. That misunderstanding contributed to delayed diagnoses and to the condition being treated as a purely reproductive issue rather than a lifelong hormonal and metabolic one.

The change followed a global process led by Monash University involving more than 50 patient and professional organisations and over 22,000 survey responses, with women living with the condition the strongest voices for change. It has been welcomed by RANZCOG and endorsed by bodies including the Endocrine Society and ASRM.

Your diagnosis, your treatment options and your care have not changed. Both names will be used side by side during a transition period, with international guidelines to be updated in 2028. If you have questions about what this means for you, call us to book an appointment with our team.

Contact us! Please visit the contact us page for more details and to send an enquiry, or call us on 1300-NEW-FAMILY (1300 639 326). We are here to answer your questions and help you along your journey.